Translational Chinese medicine is one of the latest developing fields in traditional Chinese medicine. In this paper, we discuss the “3 w” namely, “what is”, “why to advance”, “how to carry out” and the significance of translational Chinese medicine. To overcome the innate drawbacks of traditional Chinese medicine (TCM), the basic theory of TCM had better be refreshed. The safety and efficacy of classic formulae and therapy experience of TCM should be evaluated based on strict quality control and reaffirmed with evidence based medicine. The significance of translational Chinese medicine is to transform Chinese medicine into a balanced, personalized medicine with sound safety, good efficacy and strict quality control.
X. G. Sun, Q. Liu, Y. Y. Zhao and Y. Cai, “Confirmation, Falsification, or Hermeneutics?” Journal of Nanjing University of Traditional Chinese Medicine (Social Science Edition), Vol. 8, No. 1, 2007, pp. 30-33.
B. Liu, Y. Zhang, J. Hu, L. He and X. Zhou, “Thinking and Practice of Accelerating Transformation of Traditional Chinese Medicine from Experience Medicine to Evidence-Based Medicine,” Frontier Medical, Vol. 5, No. 2, 2011, pp. 163-170.
R. L. Hauger, V. Risbrough, R. H. Oakley, J. A. Olivares-Reyes and F. M. Dautzenberg, “Role of CRF Receptor Signaling in Stress Vulnerability, Anxiety, and Depression,” Annals of the New York Academy of Sciences, Vol. 1179, No. 2009, pp. 120-143.
M. W. Saif, F. Lansigan, S. Ruta, L. Lamb, M. Mezes, K. Elligers, et al., “Phase I Study of the Botanical Formulation PHY906 with Capecitabine in Advanced Pancreatic and Other Gastrointestinal Malignancies,” Phytomedicine, Vol. 17, No. 3-4, 2010, pp. 161-169.
Y. Yen, S. So, M. Rose, M. W. Saif, E. Chu, S. H. Liu, et al., “Phase I/II Study of PHY906/Capecitabine in Advanced Hepatocellular Carcinoma,” Anticancer Research, Vol. 29, No. 10, 2009, pp. 4083-4092.
X. Huang, F. Qin, H. M. Zhang, H. B. Xiao, L. X. Wang, X. Y. Zhang, et al., “Cardioprotection by Guanxin II in Rats with Acute Myocardial Infarction Is Related to Its Three Compounds,” Journal of Ethnopharmacology, Vol. 121, No. 2, 2009, pp. 268-273.
R. Tilton, A. A. Paiva, J. Q. Guan, R. Marathe, Z. Jiang, W. van Eyndhoven, et al., “A Comprehensive Platform for Quality Control of Botanical Drugs (Phytomicsqc): A Case Study of Huangqin Tang (HQT) and PHY906,” Chinese Medicine, Vol. 5, 2010, pp. 1-15.
Y. Sun, Y. Dong, H. J. Jiang, T. T. Cai, L. Chen, X. Zhou, et al., “Dissection of the Role of Paeoniflorin in the Traditional Chinese Medicinal Formula Si-Ni-San against Contact Dermatitis in Mice,” Life Sciences, Vol. 84, No. 11-12, 2009, pp. 337-344.
Y. Wang, X. Huang, F. Qin, P. Ren, Z. Zhu, R. Fan, et al., “A Strategy for Detecting Optimal Ratio of Cardioprotection-Dependent Three Compounds as Quality Control of Guan-Xin-Er-Hao Formula,” Journal of Ethnopharmacology, Vol. 133, No. 2, 2011, pp. 735-742.
Y. Li, T. Wu, H. Shang and K. Yang, “Strategies for Promoting the Development of Evidence-Based Medicine in China,” Journal of Evidence-Based Medicine, Vol. 2, No. 1, 2009, pp. 47-52.
G. K. Merijohn and M. G. Newman, “The Translational Clinical Practice System: A Way to Implement the Evidence-Based Approach in the Dental Office,” Journal of the California Dental Association, Vol. 34, No. 7, 2006, pp. 529-539.